Half-year report · HY
4574.TEDINET S100YVYD
Period2026-01-01 → 2026-06-30
Filed2026-08-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.6bn | 2026-01-01 → 2026-06-30 | Cons. | Net sales |
| Revenue | ¥6.4bn | 2025-01-01 → 2025-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.4bn | 2025-01-01 → 2025-06-30 | Cons. | Net sales |
| Operating income | ¥17m | 2026-01-01 → 2026-06-30 | Cons. | Operating income |
| Operating income | ¥46m | 2025-01-01 → 2025-06-30 | Cons. | Operating income |
| Ordinary income | ¥41m | 2026-01-01 → 2026-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥482m | 2025-01-01 → 2025-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥20m | 2025-01-01 → 2025-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥40m | 2026-01-01 → 2026-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥382m | 2025-01-01 → 2025-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥44m | 2026-01-01 → 2026-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥923m | 2025-01-01 → 2025-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥279m | 2025-01-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥44m | 2026-01-01 → 2026-06-30 | Cons. | Profit loss |
| Net income | ¥279m | 2025-01-01 → 2025-06-30 | Cons. | Profit loss |
| Total assets | ¥11.1bn | at 2026-06-30 | Cons. | Assets |
| Total assets | ¥12.3bn | at 2025-12-31 | Cons. | Assets |
| Total assets | ¥11.7bn | at 2025-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥2.7bn | at 2026-06-30 | Cons. | Liabilities |
| Total liabilities | ¥3.8bn | at 2025-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥8.4bn | at 2026-06-30 | Cons. | Net assets |
| Net assets / equity | ¥8.5bn | at 2025-12-31 | Cons. | Net assets |
| Net assets / equity | ¥7.9bn | at 2025-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.7bn | at 2026-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥4.3bn | at 2025-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.7bn | at 2026-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.3bn | at 2025-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.1bn | at 2025-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.5bn | at 2024-12-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥66m | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥814m | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥61m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥685m | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥142m | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥295m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥853m | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.2bn | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥684m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥0.89 | 2026-01-01 → 2026-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥169.51 | 2025-01-01 → 2025-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥5.57 | 2025-01-01 → 2025-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 76.0% | at 2026-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 69.4% | at 2025-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.1% | at 2025-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 26
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2026-01-01 → 2026-06-30 | ¥2m |
| Otherother segments | revenue external | 2026-01-01 → 2026-06-30 | ¥2m |
| Otherother segments | segment profit | 2026-01-01 → 2026-06-30 | −¥14m |
| Reconciling Itemsreconciling | segment profit | 2026-01-01 → 2026-06-30 | −¥433m |
| Infection Control Businessreportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥111m |
| Infection Control Businessreportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥111m |
| Infection Control Businessreportable segment | segment profit | 2026-01-01 → 2026-06-30 | −¥92m |
| Pharmaceuticals Businessreportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥2.5bn |
| Pharmaceuticals Businessreportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥2.5bn |
| Pharmaceuticals Businessreportable segment | segment profit | 2026-01-01 → 2026-06-30 | ¥557m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2026-01-01 → 2026-06-30 | ¥2.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2026-01-01 → 2026-06-30 | ¥2.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2026-01-01 → 2026-06-30 | ¥450m |
| Otherother segments | revenue | 2025-01-01 → 2025-06-30 | ¥2m |
| Otherother segments | revenue external | 2025-01-01 → 2025-06-30 | ¥2m |
| Otherother segments | segment profit | 2025-01-01 → 2025-06-30 | −¥7m |
| Reconciling Itemsreconciling | segment profit | 2025-01-01 → 2025-06-30 | −¥396m |
| Infection Control Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥203m |
| Infection Control Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥203m |
| Infection Control Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | −¥151m |
| Pharmaceuticals Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥2.2bn |
| Pharmaceuticals Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥2.2bn |
| Pharmaceuticals Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥601m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-01-01 → 2025-06-30 | ¥2.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-01-01 → 2025-06-30 | ¥2.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-01-01 → 2025-06-30 | ¥443m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 499
| Item | Context | Value | Unit |
|---|---|---|---|
| Interest expenses noe | Prior1InterimDuration | 3000000 | JPY |
| Interest expenses noe | InterimDuration | 1000000 | JPY |
| Foreign exchange losses noe | Prior1InterimDuration | 30000000 | JPY |
| Foreign exchange losses noe | InterimDuration | － | JPY |
| Other noe | Prior1InterimDuration | 5000000 | JPY |
| Other noe | InterimDuration | 1000000 | JPY |
| Non operating expenses | Prior1InterimDuration | 39000000 | JPY |
| Non operating expenses | InterimDuration | 2000000 | JPY |
| Ordinary income | Prior1InterimDuration | 20000000 | JPY |
| Ordinary income | InterimDuration | 41000000 | JPY |
| Gain on sales of investment securities ei | Prior1InterimDuration | 347000000 | JPY |
| Gain on sales of investment securities ei | InterimDuration | － | JPY |
| Compensation income ei | Prior1InterimDuration | 14000000 | JPY |
| Compensation income ei | InterimDuration | － | JPY |
| Extraordinary income | Prior1InterimDuration | 361000000 | JPY |
| Extraordinary income | InterimDuration | － | JPY |
| Impairment loss el | Prior1InterimDuration | 0 | JPY |
| Impairment loss el | InterimDuration | － | JPY |
| Loss on retirement of noncurrent assets el | Prior1InterimDuration | － | JPY |
| Loss on retirement of noncurrent assets el | InterimDuration | 0 | JPY |
| Extraordinary loss | Prior1InterimDuration | 0 | JPY |
| Extraordinary loss | InterimDuration | 0 | JPY |
| Income before income taxes | Prior1InterimDuration | 382000000 | JPY |
| Income before income taxes | InterimDuration | 40000000 | JPY |
| Income taxes current | Prior1InterimDuration | 10000000 | JPY |
| Income taxes current | InterimDuration | 14000000 | JPY |
| Income taxes deferred | Prior1InterimDuration | 92000000 | JPY |
| Income taxes deferred | InterimDuration | -18000000 | JPY |
| Income taxes | Prior1InterimDuration | 102000000 | JPY |
| Income taxes | InterimDuration | -4000000 | JPY |
| Profit loss | Prior1InterimDuration | 279000000 | JPY |
| Profit loss | InterimDuration | 44000000 | JPY |
| Profit loss attributable to owners of parent | Prior1InterimDuration | 279000000 | JPY |
| Profit loss attributable to owners of parent | InterimDuration | 44000000 | JPY |
| Profit loss | Prior1InterimDuration | 279000000 | JPY |
| Profit loss | InterimDuration | 44000000 | JPY |
| Valuation difference on available for sale securities net of tax oci | Prior1InterimDuration | -234000000 | JPY |
| Valuation difference on available for sale securities net of tax oci | InterimDuration | － | JPY |
| Foreign currency translation adjustment net of tax oci | Prior1InterimDuration | -77000000 | JPY |
| Foreign currency translation adjustment net of tax oci | InterimDuration | 12000000 | JPY |
| Other comprehensive income | Prior1InterimDuration | -312000000 | JPY |
| Other comprehensive income | InterimDuration | 12000000 | JPY |
| Comprehensive income | Prior1InterimDuration | -32000000 | JPY |
| Comprehensive income | InterimDuration | 56000000 | JPY |
| Comprehensive income attributable to owners of the parent | Prior1InterimDuration | -32000000 | JPY |
| Comprehensive income attributable to owners of the parent | InterimDuration | 56000000 | JPY |
| Income before income taxes | Prior1InterimDuration | 382000000 | JPY |
| Income before income taxes | InterimDuration | 40000000 | JPY |
| Depreciation and amortization ope cf | Prior1InterimDuration | 125000000 | JPY |
| Depreciation and amortization ope cf | InterimDuration | 148000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |